Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
US-backed Gaza aid group launches bold new system...
Biden doctor pleads the Fifth in speedy House...
Watchdog backs Rubio’s sanctions on UN official over...
Trump taps Sean Duffy to serve as interim...
Trump cautioned Putin he would ‘bomb the s—‘...
I worked for the most successful third party...
‘Gut check time’: Dissent among Senate GOP ranks...
New book reveals what Obama and ‘conqueror’ Trump...
Trump had very unexpected convo with Obama at...
10 reasons the DOJ and FBI face backlash...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

Trump’s pick to lead NIH, Dr. Jay Bhattacharya, confirmed by Senate in party-line vote

by admin March 26, 2025
March 26, 2025
Trump’s pick to lead NIH, Dr. Jay Bhattacharya, confirmed by Senate in party-line vote

The full Senate voted Tuesday evening to confirm President Donald Trump’s pick to lead the National Institutes of Health (NIH), Dr. Jay Bhattacharya.

The party-line vote followed approval from the Senate Committee on Health, Education, Labor and Pensions, which also voted along party lines to advance Bhattacharya, leading to today’s full Senate vote.  

A physician, Stanford professor of medicine and senior fellow at the university’s Institute for Economic Policy Research, Bhattacharya was a leading voice during the COVID-19 pandemic against lockdown measures and vaccine mandates. 

He was one of the co-authors of the Great Barrington Declaration, a document published in October 2020 by a group of scientists advocating against widespread COVID lockdowns and promoting the efficacy of natural immunity for low-risk individuals as opposed to vaccination.

Bhattacharya was probed by the Senate HELP Committee earlier this month over various issues related to his potential role as NIH director. However, for much of the hearing, he was forced to defend the president’s decision to cut certain research funds at NIH, including a 15% cap on indirect research costs, also known as facilities and administrative costs, dispersed by the NIH.

Bhattacharya would not explicitly say he disagreed with the cuts, or that, if confirmed, he would step in to stop them. Rather, he said he would ‘follow the law,’ while also investigating the effect of the cuts and ensuring every NIH researcher doing work that advances the health outcomes of Americans has the resources necessary.

‘I think transparency regarding indirect costs is absolutely worthwhile. It’s something that universities can fix by working together to make sure that where that money goes is made clear,’ Bhattacharya said of the indirect costs going to universities, hospitals and research clinics from the NIH. 

In addition to addressing questions about the Trump cuts, Bhattacharya also laid out what he called a new, decentralized vision for future research at NIH that he said will be aimed at embracing dissenting ideas and transparency, while focusing on research topics that have the best chance at directly benefiting health outcomes of Americans. Bhattacharya added that he wants to rid the agency’s research portfolio of other ‘frivolous’ efforts that he says do little to directly benefit health outcomes.

‘I think fundamentally what matters is do scientists have an idea that advances the scientific field they’re in?’ Bhattacharya said last week during his confirmation testimony. ‘Do they have an idea that ends up addressing the health needs of Americans?’

Prior to his confirmation, Bhattacharya, alongside several other scientists, including Trump’s pick to head the Food and Drug Administration, Dr. Marty Makary, launched a new research journal focused on spurring scientific discourse and combating ‘gatekeeping’ in the medical research community. The journal, the Journal of the Academy of Public Health (JAPH), aims to spur scientific discourse by publishing peer reviews of prominent studies from other journals that do not make their peer reviews publicly available.

This post appeared first on FOX NEWS

previous post
Senate confirms Dr Marty Makary as Trump’s FDA chief
next post
Affirm announces JPMorgan Chase merchants can now offer installment loans at checkout

You may also like

Biden-Harris admin treatment of Ukraine, Israel wars ‘differs...

November 4, 2024

Pritzker trolls Trump by ‘renaming’ Lake Michigan as...

February 9, 2025

Don’t blame your health insurance company for your...

December 29, 2024

Wasserman Schultz sparks backlash for claiming Tulsi Gabbard...

November 17, 2024

Kamala Harris’ new climate director said she is...

September 10, 2024

Russia is supplying Houthis with satellite data to...

October 26, 2024

Trump makes appearances at several Inaugural Balls around...

January 21, 2025

Nearly half of Americans back Israeli airstrikes on...

June 14, 2025

The history of Gaza amid Trump’s plan to...

February 5, 2025

Controversial defense program tied to DEI-laden contractor could...

April 17, 2025

Recent Posts

  • US-backed Gaza aid group launches bold new system to deliver food directly to families
  • Biden doctor pleads the Fifth in speedy House closed-door interview
  • Watchdog backs Rubio’s sanctions on UN official over ‘shameful efforts’ targeting US, Israel
  • Trump taps Sean Duffy to serve as interim NASA chief
  • Trump cautioned Putin he would ‘bomb the s—‘ out of Moscow if Russia invaded Ukraine, new book claims

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (819)
    • Investing (2,497)
    • Politics (3,095)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.